Global Small Molecule Drug Discovery Market Outlook, 2031

The global small molecule drug discovery industry covers the research activities, technologies and services used to identify and optimise low-molecular-weight chemical compounds that can become medicines. Small molecules, typically taken as tablets or capsules, remain the majority of approved drugs and include most cardiovascular, neurological, psychiatric, infectious disease and many cancer and immunology medicines. The discovery process includes target identification and validation, hit discovery through high-throughput screening, fragment-based screening, DNA-encoded libraries and virtual screening, hit-to-lead chemistry, lead optimisation to improve potency, selectivity and drug-like properties, and preclinical studies of absorption, distribution, metabolism, excretion and toxicity. Participants include pharmaceutical companies such as Pfizer, Merck, Novartis, Eli Lilly, AstraZeneca, Roche, Bristol Myers Squibb, AbbVie and Takeda; biotechnology companies; contract research organisations providing chemistry, biology and pharmacology services, including WuXi AppTec, Charles River Laboratories, Evotec, Pharmaron, Syngene, Sygnature Discovery and Aragen; computational and AI-driven discovery companies such as Schrödinger, Recursion, Isomorphic Labs, Insilico Medicine, Iambic, Relay Therapeutics and XtalPi; and suppliers of compound libraries, reagents, instruments and software such as Enamine, Merck KGaA, Thermo Fisher, Revvity and Dotmatics.

Small molecule drug discovery has been renewed by new technologies and targets, even as biologics and genetic medicines have taken a growing share of pharmaceutical pipelines. Advances in structural biology, cryo-electron microscopy, chemical biology and computational chemistry have made it possible to drug targets once considered undruggable, such as KRAS, and new modalities such as targeted protein degraders and molecular glues, which direct the cell's own machinery to destroy disease-causing proteins, have become major areas of research. Artificial intelligence has become central to the field: the 2024 Nobel Prize in Chemistry recognised AI-based protein structure prediction and design, AlphaFold 3 extended prediction to protein-ligand interactions in May 2024, Isomorphic Labs raised USD 600 million in March 2025, and Recursion completed its merger with Exscientia in November 2024. In June 2025, Insilico Medicine published phase 2a results for rentosertib, a drug whose target and molecule were both discovered using AI, in Nature Medicine. Small molecules have also produced notable approvals, including Vertex's non-opioid painkiller Journavx in January 2025 and Lilly's orforglipron, the first oral small-molecule GLP-1 obesity drug, approved in April 2026. Policy changes have influenced the field, including the Inflation Reduction Act's shorter period before Medicare negotiation for small molecules compared with biologics, which industry groups argue discourages small molecule investment, and the FDA's April 2025 plan to reduce animal testing in favour of new approach methodologies.

Market Dynamics Market Drivers • Advantages of Small Molecules in Access and DeliverySmall molecules can usually be taken orally, penetrate cells and the brain, be manufactured at large scale at lower cost than biologics, and be stored without refrigeration. These advantages make them attractive for chronic diseases, global access and conditions requiring brain penetration. The success of oral GLP-1 drugs such as orforglipron shows how small molecules can expand access to therapies previously available only as injections.
• AI, Computational Chemistry and New Screening TechnologiesArtificial intelligence, physics-based modelling, protein structure prediction, DNA-encoded libraries, ultra-large virtual libraries of billions of compounds and automated chemistry are speeding up hit discovery and optimisation. These technologies reduce the number of compounds that must be made and tested, shorten discovery timelines and help design drugs for difficult targets. Pharmaceutical companies are investing heavily in AI partnerships and internal computational capabilities.

Market Challenges • High Attrition and Development CostsMost small molecule candidates fail during preclinical or clinical development because of lack of efficacy, safety problems or poor drug properties. Discovering and developing a new drug can take more than a decade and cost billions of dollars including failures. AI tools have not yet proven that they substantially improve clinical success rates, and many AI-designed compounds remain in early trials.
• Policy Disincentives and Competition from Other ModalitiesUnder the US Inflation Reduction Act, small molecules can be selected for Medicare price negotiation seven years after approval compared with eleven years for biologics, which industry groups argue reduces returns on small molecule investment, although changes have been proposed. Investors and pharmaceutical companies have shifted significant resources toward biologics, antibody-drug conjugates, cell and gene therapies and RNA medicines, increasing competition for funding.

Market Trends • Targeted Protein Degradation and Molecular GluesTargeted protein degraders, including PROTACs and molecular glues, bind a disease-causing protein and an enzyme that tags it for destruction, allowing drugs to eliminate proteins rather than just inhibit them. Companies such as Arvinas, Kymera, C4 Therapeutics, Monte Rosa, Nurix and large pharmaceutical groups are developing degraders for cancer, immunology and neurology, and vepdegestrant for breast cancer has reached late-stage development.
• AI-Native Discovery and Automated LaboratoriesAI-first companies combine machine learning, large biological and chemical datasets and automated laboratories that design, make and test compounds in closed loops. Pharmaceutical companies have signed large partnerships with Isomorphic Labs, Recursion, Insilico, XtalPi and others, and technology companies such as Nvidia, Google and Microsoft provide computing platforms, including Lilly's AI supercomputer built with Nvidia and announced in October 2025.



Segment Analysis Lead optimisation and hit identification account for the largest shares of small molecule discovery spending, while target identification and validation is growing with advances in genomics and AI. Target identification and validation uses genomics, proteomics, human genetics, functional screens such as CRISPR screens, and literature and data mining to find proteins or pathways that drive disease and confirm that modulating them could provide therapeutic benefit. Large human genetic and proteomic datasets have improved target selection. Hit identification finds compounds that interact with a target, using high-throughput screening of compound libraries, fragment-based screening, DNA-encoded library screening, affinity selection mass spectrometry, phenotypic screening and virtual screening of ultra-large libraries. Hit-to-lead chemistry improves initial hits into lead series with better potency and properties. Lead optimisation, typically the most resource-intensive discovery stage, uses iterative design, synthesis and testing to improve potency, selectivity, pharmacokinetics, safety and manufacturability, involving medicinal chemistry, structural biology and in vitro and in vivo pharmacology. Preclinical candidate selection and IND-enabling studies, including toxicology, safety pharmacology and formulation, prepare compounds for clinical trials. Discovery services also include compound management, synthesis of building blocks and analytical chemistry. AI and computational tools are increasingly applied across all stages.

High-throughput screening, structure-based design and computational methods are the core technologies of small molecule discovery, with AI and DNA-encoded libraries among the fastest-growing approaches. High-throughput screening uses robotics, miniaturised assays and detection systems to test hundreds of thousands to millions of compounds against a target, and remains a mainstay of hit discovery at large companies and contract research organisations. Structure-based drug design uses X-ray crystallography, cryo-electron microscopy and nuclear magnetic resonance to understand how compounds bind targets and to guide chemistry. Fragment-based drug discovery screens small chemical fragments that are then grown or linked into potent compounds. DNA-encoded libraries allow billions of compounds, each tagged with a DNA barcode, to be screened in a single experiment. Computational chemistry, including molecular docking, physics-based free energy calculations and virtual screening, predicts how compounds bind and behave, with Schrödinger a leading software provider. AI and machine learning models generate new molecules, predict properties and prioritise compounds for synthesis, and generative AI and protein structure prediction tools such as AlphaFold have expanded capabilities. Phenotypic screening tests compounds in cells or organisms without a predefined target. Automated synthesis and robotic laboratories accelerate make-test cycles. Chemoproteomics and covalent drug discovery identify binding sites on challenging proteins.

Oncology is the largest therapeutic area for small molecule drug discovery, while neurology, immunology, metabolic diseases and infectious diseases are major and growing areas. Oncology accounts for the largest share of small molecule discovery activity, including kinase inhibitors, KRAS inhibitors, PARP inhibitors, epigenetic drugs, targeted protein degraders and synthetic lethality approaches, and many targeted cancer drugs approved in recent years are small molecules. Neurology and psychiatry are important areas because small molecules can cross the blood-brain barrier, with research on pain, depression, schizophrenia, Alzheimer's disease, Parkinson's disease and epilepsy; recent successes include suzetrigine for acute pain and muscarinic agonists for schizophrenia. Immunology and inflammation include JAK and TYK2 inhibitors, oral IL-17 and IL-23 pathway drugs and other oral alternatives to biologics. Metabolic and cardiovascular diseases have seen renewed small molecule interest, including oral GLP-1 agonists, oral PCSK9 inhibitors, aldosterone synthase inhibitors and lipoprotein(a) inhibitors. Infectious diseases, including antibiotics, antivirals and antifungals, rely heavily on small molecules, although commercial incentives are weak for antibiotics. Rare diseases, including cystic fibrosis modulators and small molecules for genetic disorders, are an active area. Respiratory, gastrointestinal and dermatology indications form further areas.

Pharmaceutical and biotechnology companies are the main performers and funders of small molecule discovery, while contract research organisations and AI-driven discovery companies perform a growing share of the work. Large pharmaceutical companies conduct extensive in-house small molecule discovery with large compound libraries, screening facilities and medicinal chemistry teams, but they increasingly outsource parts of the process and partner externally. Biotechnology companies, including venture-backed start-ups, often focus on specific targets or platforms and depend on contract research organisations for much of their chemistry and biology work. Contract research organisations, such as WuXi AppTec, Pharmaron, Charles River Laboratories, Evotec, Syngene, Sygnature Discovery, Aragen and Jubilant Biosys, provide integrated discovery services, including chemistry, biology, DMPK and toxicology, with large operations in China and India. Geopolitical tensions, including the BIOSECURE Act enacted in December 2025 and the addition of WuXi AppTec to the US Department of Defense's 1260H list in June 2026, are prompting some Western companies to diversify away from Chinese providers. AI-driven discovery companies, including Isomorphic Labs, Recursion, Insilico Medicine, XtalPi, Iambic and Relay Therapeutics, develop their own pipelines and partner with pharmaceutical companies. Academic and research institutes, including university drug discovery centres and government programmes, generate early targets and chemical probes. Non-profit organisations and product development partnerships support discovery for neglected diseases.

Regional Analysis North America leads the small molecule drug discovery market because of large pharmaceutical and biotechnology R&D spending, venture funding and AI discovery companies, while Asia-Pacific, especially China and India, is a major and growing centre for outsourced discovery services. North America, led by the United States, accounts for the largest share of small molecule discovery spending, with major pharmaceutical research centres, thousands of biotechnology companies in hubs such as Boston, San Francisco and San Diego, and leading AI discovery companies, including Recursion, Schrödinger, Relay and Iambic. US policy developments, including the Inflation Reduction Act's treatment of small molecules, the FDA's plan to reduce animal testing and the BIOSECURE Act, influence discovery strategies. Canada has growing AI and discovery capabilities in Toronto and Montreal. Europe is the second largest region, with strong pharmaceutical research in the UK, Switzerland, Germany, Denmark, France and Belgium, contract research organisations such as Evotec and Sygnature Discovery, and AI companies such as Isomorphic Labs in London. Asia-Pacific is the fastest-growing region and a major provider of outsourced discovery chemistry and biology. China hosts large contract research organisations, including WuXi AppTec and Pharmaron, and a growing number of innovative biotechnology companies whose small molecules are licensed by Western companies, though US restrictions are encouraging diversification. India is a major provider of discovery services through Syngene, Aragen, Jubilant and others and is benefiting from diversification away from China. Japan and South Korea have strong pharmaceutical research, and Singapore and Australia have growing discovery ecosystems. Latin America, the Middle East and Africa have smaller discovery sectors, with growing investment in Israel and the Gulf states.

Key Developments April 2026: Eli Lilly's Foundayo became the first oral small-molecule GLP-1 receptor agonist approved for chronic weight management, highlighting the role of small molecules in expanding access.
June 2025: Insilico Medicine published phase 2a results in Nature Medicine for rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis whose target and molecule were identified using AI.
April 2025: The FDA announced a roadmap to phase out animal testing requirements for some drugs, beginning with monoclonal antibodies, in favour of new approach methodologies such as organoids and computer models.
March 2025: Alphabet's AI drug discovery company Isomorphic Labs raised its first external funding round to advance its AI-designed drug programmes toward clinical trials.
January 2025: Vertex's small-molecule NaV1.8 inhibitor became the first new class of non-opioid pain medicine approved in more than two decades.
November 2024: Recursion completed its combination with Exscientia, creating one of the largest AI-driven drug discovery companies with multiple clinical programmes.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Small Molecule Drug Discovery Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Discovery Stage
• Target Identification and Validation
• Hit Identification
• Hit-to-Lead
• Lead Optimisation
• Preclinical Candidate Selection

By Technology
• High-Throughput Screening
• Structure-Based Drug Design
• Fragment-Based Drug Discovery
• DNA-Encoded Libraries
• Computational Chemistry and AI
• Phenotypic Screening

By Therapeutic Area
• Oncology
• Neurology and Psychiatry
• Immunology and Inflammation
• Metabolic and Cardiovascular Diseases
• Infectious Diseases
• Rare Diseases

By End User
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organisations
• AI Drug Discovery Companies
• Academic and Research Institutes